Molecular Formula | C22H24ClN3O4 |
Molar Mass | 429.9 |
Melting Point | 223-225°C |
Boling Point | 548.2°C at 760 mmHg |
Flash Point | 285.4°C |
Solubility | Soluble in DMSO (3 mg/ml), methanol (sparingly), water (<1 mg/ml), and ethanol (<1 mg/m |
Vapor Presure | 4.52E-12mmHg at 25°C |
Appearance | Yellow powder. |
Color | White or off-white |
pKa | pKa (25°): 5.42 |
Storage Condition | Inert atmosphere,Store in freezer, under -20°C |
Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months. |
Use | HER-1 / EGFR tyrosine kinase inhibitor |
In vitro study | Erlotinib acts on HNS human head and neck tumor cells and effectively inhibits EGFR autophosphorylation. HNS human head and neck tumor cells are cell lines that express high levels of EGFR. Erlotinib had no effect on SBC-5 cell proliferation. In contrast, Erlotinib significantly inhibited PC-9 cell proliferation in a dose-dependent manner, with PC-9 cells containing a deletion mutation in exon 19 of the EGFR gene. Erlotinib treatment also did not affect SBC-5 cell migration. Erlotinib inhibited HPAC and Capan-1 cell growth with IC50 of 1.1 and 3 µm, respectively. 10 uM Erlotinib inhibits EGFR phosphorylation at Y845 (Src-dependent phosphorylation) and Y1068 (autophosphorylation) sites. Erlotinib inhibits extracellular signal-regulated kinases, Akt, and S6 only in the most sensitive cell lines. |
In vivo study | Erlotinib alone inhibits tumor growth in the H460a tumor model in a dose-dependent manner and is related to circulating levels of the drug. |
Safety Description | 24/25 - Avoid contact with skin and eyes. |
HS Code | 29335990 |